An intra-patient dose-escalation study of disodium pamidronate plus radiotherapy versus radiotherapy alone for the treatment of osteolytic metastases: Monitoring of recalcification using image-processing techniques

Strahlentherapie und Onkologie

Volumn 179, Issue 7, 2003, Pages 471-479

  Kouloulias, E Vassilis ^a,b   Kouvaris, R John ^a   Antypas, Christos ^a   Mystakidou, Kyriaki ^a   Matsopoulos, George ^b   Uzunoglu, C Nikolaos ^b   Moulopoulos, Antzela ^a   Vlahos, J Lambros ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b NATIONAL TECHNICAL UNIVERSITY OF ATHENS   (Greece)

Author keywords

Disodium pamidronate; Dose escalation; Image processing; Osteolytic metastases; Palliation; Radiotherapy

Indexed keywords

PAMIDRONIC ACID;

ADULT; ARTICLE; BONE MASS; BONE METASTASIS; BONE RADIOGRAPHY; CALCIFICATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; ELECTRON; ENERGY; FEMALE; HISTOGRAM; HUMAN; IMAGE PROCESSING; MALE; MORBIDITY; OSSIFICATION; OSTEOLYSIS; PALLIATIVE THERAPY; PATIENT MONITORING; RADIATION DOSE; TREATMENT OUTCOME; TREATMENT PLANNING; WEIGHT BEARING;

EID: 0038747965     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-003-0978-3     Document Type: Article

References (40)

1. Adamietz IA, Schneider O, Muller RP. Results of a nationwide survey on radiotherapy of bone metastases in Germany. Strahlenther Onkol 2002;178: 531-6.
2. Alhava EM. Bone density measurements. Calcif Tissues Int 1991;49:21-3.
3. Avioli LB, Lindsay R. The female osteoporotic syndrome(s). In: Avioli LV, Krane SM, eds. Metabolic bone disease and clinically related disorders. Philadelphia: Saunders, 1990:397-451.
4. Berenson JR, Lipton A. Bisphosphonates in the treatment of malignant bone disease. Annu Rev Med 1999;50:237-48.
5. Bocchi L, Coppini G, De Dominicis R, Valli G. Tissue characterization from X-ray images. Med Eng Phys 1997;19:336-42.
6. Conte PF, Latreille J, Mauriac L, Calabresi F, Santos R, Campos D, Bonneterre J, Francini G, Ford JM. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. J Clin Oncol 1996;14:2552-9.
7. Coukell AJ, Markham A. Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcemia and Paget's disease of bone. Drugs Aging 1998;12:149-68.
8. Daley-Yates PT, Dodwell DJ, Pongehaidecha M, Coleman RE, Howell A. The clearance and bioavailability of pamidronate in patients with breast cancer and bone metastases. Calcif Tissue Int 1991;49:433-5.
9. Diel JJ, Mundy GR. Bisphosphonates in the adjuvant treatment of cancer: experimental evidence and first clinical results. International Bone and Cancer Study Group (IBCG). Br J Cancer 2000;82:1381-6.
10. Hildebolt CF, Brunsden B, Yokoyama-Crothers N, Pilgram TK, Townsend KE, Vannier MW, Shrout MK. Comparison of reliability of manual and computer-intensive methods for radiodensity measures of alveolar bone loss. Dentomaxillofac Radiol 1999;27:245-50.
11. Hillner BE, Ingle JN, Berenson JR, Janjan NA, Albain KS, Lipton A, Yee G, Biermann JS, Chlebowski RT, Pfister DG. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol 2000;18:1378-91.
12. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996;335:1785-91.
13. Koswig S, Budach V. Remineralisation and pain relief in bone metastases after different radiotherapy fractions (10 times 3 Gy vs. 1 time 8 Gy). A prospective study. Strahlenther Onkol 1999;175:500-8.
14. Koswig S, Buchali A, Bohmer D, Schlenger L, Budach V. Palliative radiotherapy of bone metastases. A retrospective analysis of 176 patients. Strahlenther Onkol 1999;175:509-14.
15. Kouloutias V, Antypas C, Dardoufas C, Kouvaris J, Sandilos P, Seferlis S, Matsopoulos G, Uzunoglou N, Asvestas P, Vlahos L. Evaluation of recalcification of bone metastases after radiotherapy and I.V. infusion of disodium pamidronate, using image processing techniques. Comparative assessment using measurements of the optical density of plain radiography. Physica Medica 2001;XVII:17-24.
16. Kouloulias V, Dardoufas C, Kouvaris J, Antypas C, Sandilos P, Matsopoulos G, Vlahos L. New approach in the evaluation of the use of disodium pamidronate in conjunction with radiotherapy in the management of bone metastases using image processing techniques. Acta Oncol 2002;41: 169-74.
17. Kouloulias V, Dardoufas C, Kouvaris J, Gennatas C, Vlahos L. A comment from a radiotherapeutic point of view, regarding the ASCO guidelines on the role of bisphosphonates in breast cancer. J Clin Oncol 2001;19:2106.
18. Lipton A. Bisphosphonates and breast carcinoma: present and future. Cancer 2000;88:Suppl:3033-7.
19. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
20. Morton AR, Cantrill JA, Pillai GV, McMahon A, Anderson OC, Howell A. Sclerosis of lytic bone metastases after disodium aminohydroypropyliden biphosphonate (APO) in patients with breast cancer. Br Med J 1988;297: 772-3.
21. Nilsson M, Bohnell O, Jonsson K, Redlund-Johnell I. Quantitative computed tomography in measurement of vertebral trabecular bone mass. A modified method. Acta Radiol 1988;29:719-25.
22. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
23. Pratt WK. Digital image processing. New York: Wiley & Sons, 1991:243, 497, 559-63, 584-7.
24. Prise P, Hoskin PJ, Easton O, Yarnold JR. Prospective randomized trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases. Radiother Oncol 1986;6:247-55.
25. Purohit OP, Anthony C, Radsone CR, Owen J, Coleman RE. High dose intravenous pamidronate for metastatic bone pain. Br J Cancer 1994;70:554-8.
26. Revilla M, Arribas I, Sanchez-Chapado M, Villa LF, Bethencourt F, Rico H. Total and regional bone mass and biochemical markers of bone remodeling in metastatic prostate cancer. Prostate 1998;35:243-7.
27. Rizzolli R, Forni M, Schaad MA, Slosman OO, Sappino AP, Garcia J, Bonjour JP. Effects of oral clodronate on bone mineral density in patients with relapsing breast cancer. Bone 1996;6:531-7.
28. Rose CM, Kagan AR. The final report of the expert panel for the radiation oncology bone metastasis work group of the American College of Radiology. Int J Radiat Oncol Biol Phys 1998;40:1117-24.
29. Schlosser K, Scigalla P. Biochemical markers as surrogates in clinical trials in patients with metastatic bone disease and osteoporosis. Scand J Clin Lab Invest Suppl 1997;227:21-B.
30. Shapiro CL, Keating J, Angell JE, Janicek M, Gelman R, Hayes O, LeBoff MS. Monitoring therapeutic response in skeletal metastases using dual-energy X-ray absorptiometry: a prospective feasibility study in breast cancer patients. Cancer Invest 1999;17:566-74.
31. Sidney Siegel NJ Jr. Castellan nonparametric statistics for the behavioral sciences. New York: McGraw-Hill College Div, 1988.
32. Skolyszewski J, Sas-Korczynska B, Korzeniowski S, Reinfuss M. The efficiency and tolerance of half-body irradiation (HBI) in patients with multiple metastases. The Krakow experience. Strahlenther Onkol 2001;177: 482-6.
33. Southard TE, Southard KA. Detection of simulated osteoporosis in maxillae using radiographic texture analysis. IEEE Trans Biomed Eng 1996;43: 123-32.
34. Taylor AK, Lundy MW, Libant CR, Baylink DJ. Diagnostic test for metabolic bone and mineral disorders. In: Manolagas SC, Olefsky JM, eds. Metabolic bone and mineral disorders. New York: Churchill Livingstone, 1988:33-62.
35. Theriault RL, Lipton A, Hortobagyi GN, Leff R, Gluck S, Stewart JF, Costello S. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone Lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999;17:848-54.
36. Thomas SJ. Relative electron density calibration of CT scanners for radiotherapy treatment planning. Br J Radiol 1999;72:781-6.
37. Thurlimann B, Morant R, Jungi WF, Radziwill A. Pamidronate for pain control in patients with malignant osteolytic bone disease: a prospective dose-effect study. Support Care Cancer 1994;2:61-5.
38. Tomita F, Tsuji S. Computer analysis of visual textures. The Kluwer International Series in Engineering and Computer Science. Boston: Kluwer Academic, 1990:13-36.
39. Trombetti A, Arlot M, Thevenon J, Uebelhart B, Meunier PJ. Effect of multiple intravenous pamidronate courses in Paget's disease of bone. Rev Rhum Engl Ed 1999;66:467-76.
40. Wachenfeld I, Sanner G, Bottcher HO, Kollath J. The remineralization of the vertebral metastases of breast carcinoma after radiotherapy. Strahlenther Onkol 1996;172:332-41.